MARKET

ALEC

ALEC

ALECTOR, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.23
-0.36
-1.84%
After Hours: 19.23 0 0.00% 16:00 09/18 EDT
OPEN
19.55
PREV CLOSE
19.59
HIGH
19.89
LOW
19.12
VOLUME
992.24K
TURNOVER
--
52 WEEK HIGH
27.00
52 WEEK LOW
13.64
MARKET CAP
1.31B
P/E (TTM)
-15.2728
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALEC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALEC News

  • Buy Bellus Health Before It Hits The Nasdaq
  • Seeking Alpha - Article.3d ago
  • Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia
  • GlobeNewswire.09/09 13:00
  • Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia
  • Benzinga.09/09 12:05
  • Alector to Present at 17th Annual Morgan Stanley Global Healthcare Conference
  • GlobeNewswire.09/03 20:10

More

Industry

Biotechnology & Medical Research
-0.65%
Pharmaceuticals & Medical Research
-0.05%

Hot Stocks

Name
Price
%Change

About ALEC

Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).
More

Webull offers Alector Inc (ALEC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.